%0 Journal Article
%A Vera, R
%A Dotor, E
%A Feliu, J
%A González, E
%A Laquente, B
%A Macarulla, T
%A Martínez, E
%A Maurel, J
%A Salgado, M
%A Manzano, J L
%T SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
%D 2016
%@ 1699-048X
%U http://hdl.handle.net/10668/2590
%X Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.
%K Pancreatic cancer
%K Treatment
%K Diagnostic
%K Guidelines
%K Neoplasias pancreáticas
%K Guías de práctica clínica como asunto
%K Factores de riesgo
%K España
%K Humanos
%~